Overview

A 42-day Parallel Group Safety Study of Revefenacin and Formoterol, Administered in Sequence and as a Combination, in Participants With COPD

Status:
Completed

Trial end date:
2018-09-25

Target enrollment:

Participant gender:

Summary

The primary objective of the study was to characterize the safety and tolerability of once-daily revefenacin inhalation solution when dosed sequentially with twice-daily formoterol inhalation solution (PERFOROMIST®) compared to PERFOROMIST®, in a population of participants with moderate-to-very severe Chronic Obstructive Pulmonary Disease (COPD) over 21 days.

Phase:

Phase 3

Details

Lead Sponsor:

Mylan Inc.
Theravance Biopharma

Collaborators:

Mylan Inc.
Theravance Biopharma

Treatments:

Formoterol Fumarate
Pharmaceutical Solutions